Continuation treatment of chronic depression: a comparison of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination.

James H. Kocsis, A. John Rush, John C. Markowitz, Frances E. Borian, David L. Dunner, Lorrin M. Koran, Daniel N. Klein, Madhukar H. Trivedi, Bruce Arnow, Gabor Keitner, Susan G. Kornstein, Martin B. Keller

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Little is known about the relative benefits of psychotherapy, medication, and combined treatment as continuation therapies for chronic forms of major depressive disorder (MDD) after a positive response to acute treatment. We hypothesize that combined treatment would demonstrate superior continuation phase outcomes compared to either monotherapy, as evidenced by lower relapse rates and greater rates of improvement from partial to full remission. We report 16-week continuation phase outcomes for 324 patients who had participated in either the acute phase of a randomized multicenter trial of nefazodone, Cognitive Behavioral Analysis System of Psychotherapy (CBASP), or combination therapy (COMB) for chronic forms of MDD. Patients entering the continuation phase had either fully or partially remitted after 12 weeks of acute phase treatment. The primary efficacy measure was the 24-item Hamilton Rating Scale for Depression. For patients in remission at acute phase exit, 73.3% (107/146) maintained their remitted status at endpoint of the continuation phase. Of those having a partial remission at acute phase exit, 52.9% (92/174) achieved full remission by end of continuation. A greater proportion of patients maintained a partial or full remission status on COMB (90%) compared to nefazodone (80%, p=0.011) or to CBASP (82%, p=0.042). These differences reflected greater symptom re-emergence in the partial remission groups on CBASP and nefazodone monotherapy compared to COMB. Continuation treatment assignment was not randomized or blinded. There was no placebo group. Most patients with chronic forms of MDD sustained their acute phase response and more than 50% of partial remitters achieved full remission while continuing treatment with nefazodone, CBASP, or COMB. COMB was associated with less symptom re-emergence during the continuation phase than either monotherapy, particularly for partial remitters.

Original languageEnglish (US)
Pages (from-to)73-87
Number of pages15
JournalPsychopharmacology Bulletin
Volume37
Issue number4
StatePublished - 2003

Fingerprint

Psychotherapy
Depression
Major Depressive Disorder
Therapeutics
nefazodone
Acute-Phase Reaction
Multicenter Studies
Placebos
Recurrence

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health

Cite this

Kocsis, J. H., Rush, A. J., Markowitz, J. C., Borian, F. E., Dunner, D. L., Koran, L. M., ... Keller, M. B. (2003). Continuation treatment of chronic depression: a comparison of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. Psychopharmacology Bulletin, 37(4), 73-87.

Continuation treatment of chronic depression : a comparison of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. / Kocsis, James H.; Rush, A. John; Markowitz, John C.; Borian, Frances E.; Dunner, David L.; Koran, Lorrin M.; Klein, Daniel N.; Trivedi, Madhukar H.; Arnow, Bruce; Keitner, Gabor; Kornstein, Susan G.; Keller, Martin B.

In: Psychopharmacology Bulletin, Vol. 37, No. 4, 2003, p. 73-87.

Research output: Contribution to journalArticle

Kocsis, JH, Rush, AJ, Markowitz, JC, Borian, FE, Dunner, DL, Koran, LM, Klein, DN, Trivedi, MH, Arnow, B, Keitner, G, Kornstein, SG & Keller, MB 2003, 'Continuation treatment of chronic depression: a comparison of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination.', Psychopharmacology Bulletin, vol. 37, no. 4, pp. 73-87.
Kocsis, James H. ; Rush, A. John ; Markowitz, John C. ; Borian, Frances E. ; Dunner, David L. ; Koran, Lorrin M. ; Klein, Daniel N. ; Trivedi, Madhukar H. ; Arnow, Bruce ; Keitner, Gabor ; Kornstein, Susan G. ; Keller, Martin B. / Continuation treatment of chronic depression : a comparison of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. In: Psychopharmacology Bulletin. 2003 ; Vol. 37, No. 4. pp. 73-87.
@article{7773eb78c5b744359a11ddef87563078,
title = "Continuation treatment of chronic depression: a comparison of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination.",
abstract = "Little is known about the relative benefits of psychotherapy, medication, and combined treatment as continuation therapies for chronic forms of major depressive disorder (MDD) after a positive response to acute treatment. We hypothesize that combined treatment would demonstrate superior continuation phase outcomes compared to either monotherapy, as evidenced by lower relapse rates and greater rates of improvement from partial to full remission. We report 16-week continuation phase outcomes for 324 patients who had participated in either the acute phase of a randomized multicenter trial of nefazodone, Cognitive Behavioral Analysis System of Psychotherapy (CBASP), or combination therapy (COMB) for chronic forms of MDD. Patients entering the continuation phase had either fully or partially remitted after 12 weeks of acute phase treatment. The primary efficacy measure was the 24-item Hamilton Rating Scale for Depression. For patients in remission at acute phase exit, 73.3{\%} (107/146) maintained their remitted status at endpoint of the continuation phase. Of those having a partial remission at acute phase exit, 52.9{\%} (92/174) achieved full remission by end of continuation. A greater proportion of patients maintained a partial or full remission status on COMB (90{\%}) compared to nefazodone (80{\%}, p=0.011) or to CBASP (82{\%}, p=0.042). These differences reflected greater symptom re-emergence in the partial remission groups on CBASP and nefazodone monotherapy compared to COMB. Continuation treatment assignment was not randomized or blinded. There was no placebo group. Most patients with chronic forms of MDD sustained their acute phase response and more than 50{\%} of partial remitters achieved full remission while continuing treatment with nefazodone, CBASP, or COMB. COMB was associated with less symptom re-emergence during the continuation phase than either monotherapy, particularly for partial remitters.",
author = "Kocsis, {James H.} and Rush, {A. John} and Markowitz, {John C.} and Borian, {Frances E.} and Dunner, {David L.} and Koran, {Lorrin M.} and Klein, {Daniel N.} and Trivedi, {Madhukar H.} and Bruce Arnow and Gabor Keitner and Kornstein, {Susan G.} and Keller, {Martin B.}",
year = "2003",
language = "English (US)",
volume = "37",
pages = "73--87",
journal = "Psychopharmacology Bulletin",
issn = "0048-5764",
publisher = "MedWorks Media LLC",
number = "4",

}

TY - JOUR

T1 - Continuation treatment of chronic depression

T2 - a comparison of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination.

AU - Kocsis, James H.

AU - Rush, A. John

AU - Markowitz, John C.

AU - Borian, Frances E.

AU - Dunner, David L.

AU - Koran, Lorrin M.

AU - Klein, Daniel N.

AU - Trivedi, Madhukar H.

AU - Arnow, Bruce

AU - Keitner, Gabor

AU - Kornstein, Susan G.

AU - Keller, Martin B.

PY - 2003

Y1 - 2003

N2 - Little is known about the relative benefits of psychotherapy, medication, and combined treatment as continuation therapies for chronic forms of major depressive disorder (MDD) after a positive response to acute treatment. We hypothesize that combined treatment would demonstrate superior continuation phase outcomes compared to either monotherapy, as evidenced by lower relapse rates and greater rates of improvement from partial to full remission. We report 16-week continuation phase outcomes for 324 patients who had participated in either the acute phase of a randomized multicenter trial of nefazodone, Cognitive Behavioral Analysis System of Psychotherapy (CBASP), or combination therapy (COMB) for chronic forms of MDD. Patients entering the continuation phase had either fully or partially remitted after 12 weeks of acute phase treatment. The primary efficacy measure was the 24-item Hamilton Rating Scale for Depression. For patients in remission at acute phase exit, 73.3% (107/146) maintained their remitted status at endpoint of the continuation phase. Of those having a partial remission at acute phase exit, 52.9% (92/174) achieved full remission by end of continuation. A greater proportion of patients maintained a partial or full remission status on COMB (90%) compared to nefazodone (80%, p=0.011) or to CBASP (82%, p=0.042). These differences reflected greater symptom re-emergence in the partial remission groups on CBASP and nefazodone monotherapy compared to COMB. Continuation treatment assignment was not randomized or blinded. There was no placebo group. Most patients with chronic forms of MDD sustained their acute phase response and more than 50% of partial remitters achieved full remission while continuing treatment with nefazodone, CBASP, or COMB. COMB was associated with less symptom re-emergence during the continuation phase than either monotherapy, particularly for partial remitters.

AB - Little is known about the relative benefits of psychotherapy, medication, and combined treatment as continuation therapies for chronic forms of major depressive disorder (MDD) after a positive response to acute treatment. We hypothesize that combined treatment would demonstrate superior continuation phase outcomes compared to either monotherapy, as evidenced by lower relapse rates and greater rates of improvement from partial to full remission. We report 16-week continuation phase outcomes for 324 patients who had participated in either the acute phase of a randomized multicenter trial of nefazodone, Cognitive Behavioral Analysis System of Psychotherapy (CBASP), or combination therapy (COMB) for chronic forms of MDD. Patients entering the continuation phase had either fully or partially remitted after 12 weeks of acute phase treatment. The primary efficacy measure was the 24-item Hamilton Rating Scale for Depression. For patients in remission at acute phase exit, 73.3% (107/146) maintained their remitted status at endpoint of the continuation phase. Of those having a partial remission at acute phase exit, 52.9% (92/174) achieved full remission by end of continuation. A greater proportion of patients maintained a partial or full remission status on COMB (90%) compared to nefazodone (80%, p=0.011) or to CBASP (82%, p=0.042). These differences reflected greater symptom re-emergence in the partial remission groups on CBASP and nefazodone monotherapy compared to COMB. Continuation treatment assignment was not randomized or blinded. There was no placebo group. Most patients with chronic forms of MDD sustained their acute phase response and more than 50% of partial remitters achieved full remission while continuing treatment with nefazodone, CBASP, or COMB. COMB was associated with less symptom re-emergence during the continuation phase than either monotherapy, particularly for partial remitters.

UR - http://www.scopus.com/inward/record.url?scp=4644324724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644324724&partnerID=8YFLogxK

M3 - Article

C2 - 15131518

AN - SCOPUS:4644324724

VL - 37

SP - 73

EP - 87

JO - Psychopharmacology Bulletin

JF - Psychopharmacology Bulletin

SN - 0048-5764

IS - 4

ER -